Lyell Immunopharma, Inc.
$12.57
-16%Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -0.8).
Valuation inputs: P/E -0.8, earnings yield N/A, momentum -15.6%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -1.1%, ROIC -70.1%).
Profitability stack: net margin -7623.6%, ROE -1.1%, ROIC -70.1%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +27.0%, momentum -15.6%, net margin -7623.6%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Lyell Immunopharma, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Lyell Immunopharma, Inc. Fair Value Envelope
Lyell Immunopharma, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Lyell Immunopharma, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Lyell Immunopharma, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Lyell Immunopharma, Inc. Street Expectations Map
Wall Street analysts project that LYEL stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 46.00, with estimates ranging from a low of 44.00 to a high of 49.00.
The consensus 1-year price target stands at 46.00, with estimates ranging from a low of 44.00 to a high of 49.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Lyell Immunopharma, Inc. Insider Positioning
During the last 12 months, insiders have purchased $30.48M and sold $486K worth of LYEL shares, resulting in $29.99M of net buying activity.
3 Months
976.2K
25.00M
0
0.00
+25.0M
+$25.00M
3-6 Months
0
0.00
13.4K
338.46K
-338K
-$338K
6-9 Months
318.0K
5.48M
884
14.24K
+5.5M
+$5.46M
9-12 Months
0
0.00
12.7K
133.55K
-134K
-$134K
Top Buyers
Arch Venture Fund Xiii, L.P.
10 Percent Owner
$12.50M
Arch Venture Partners Ix, Llc
10 Percent Owner
$12.50M
Seely Lynn
Director, Officer: President And Ceo
$3.02M
Hill Stephen J.
Officer: Chief Operating Officer
$1.29M
Lee Gary K.
Officer: Chief Scientific Officer
$1.17M
Top Sellers
Seely Lynn
Director, Officer: President And Ceo
$276K
Bulis Veronica Sanchez
Officer: Vp, Corporate Controller
$84K
Lee Gary K.
Officer: Chief Scientific Officer
$63K
Hill Stephen J.
Officer: Chief Operating Officer
$45K
Newton Charles W.
Officer: Chief Financial Officer
$18K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $29.99M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
No Dividend Yield Data
LYEL has not reported any dividend yield values in the available annual periods.
lyel Dividend History
Learning Layer
Related Guides
Build conviction on LYEL by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.